News items Dutch Childrens Formulary now also in use abroad
30 April 2021

The Kinderformularium, developed in the Netherlands, now also provides pediatricians and pharmacists abroad with a database of drug dosage recommendations specifically aimed at treating children. Germany, Austria and Norway are the first countries in which the Kinderformularium has been rolled out. All parties signed a license agreement with the Dutch Children's Formulary NKFK (Nederlands Kenniscentrum Farmacotherapie bij Kinderen).

Saskia de Wildt, Medical Director and Pediatrician, Professor of Clinical Pharmacology at the Radboudumc: 'The Children's Formulary is unique. It has taken a lot of time and effort to set it up properly and carefully and to develop it further. For this we worked together with a large network of Dutch physicians and pharmacists. We received financial support from various parties, and since 2017 the Ministry of Health, Welfare and Sport has been funding our Dutch activities.'

'It requires continuous monitoring to see if the data is still up to date and meets all the conditions of medication for children. I am very proud and happy that the Children's Formulary is now also used outside the Netherlands and that this allows us to share our child-specific drug dosage information system with other countries. We look forward to other countries joining us so that we can also contribute to safer and more effective drug care for children there.

Customization possible per country

It is possible to adapt the system to the needs of the country concerned. All countries carefully checked the existing content, and where necessary, the database was expanded to include medicines that are not used in the Netherlands but are used in the country in question.
Tjitske van der Zanden, technical director of the Children's Formulary and researcher at Radboudumc and Erasmus MC: "The ultimate goal is to collaborate on content. By drawing up the dosage recommendations together we can divide the work, speed up the maintenance cycle and further expand the information, for example with dosages for obese children or children born prematurely. For us, the most important thing is that we can ensure that children in all countries receive the right medication in the right dosage, this is a great first step!'

More information


Margie Alders

persvoorlichter

+31622421639
neem contact op

Related news items


Call Dutch L’Oréal UNESCO for Women in Science fellowships

12 May 2021

The Fondation L’Oréal and UNESCO invite you to nominate eminent women scientists for the 2022 L’Oréal-UNESCO For Women in Science International Awards. Deadline 31 May 2021.

read more

Dried pepper and video games: novel proteins to generate small RNAs

11 May 2021

Joep Joosten and colleagues determined the composition of PIWI protein complexes to provide novel insights into the piRNA pathway of virus-transmitting mosquitoes. They published this recently in Cell reports.

read more

Four NWO Open Competition Grants for Radboud researchers

11 May 2021

Four researchers from Radboud University and Radboudumc receive a NWO Open Competion grant from the NWO Domain Social Sciences and Humanities.

read more

Miniaturized microfluidic platform for automated epigenetic profiling

6 May 2021

Together with Fluidigm, a US-based company focusing on microfluidics, the team of Hendrik Marks publishes in Genome Research the development of a powerful plug and play ChIP-seq platform for minute amount of cells, such as embryonic specimens or small biopsies.

read more

Broken teeth coronastress poses a danger to our teeth

6 May 2021

Teeth grinding and molars on top of each other: stress from corona causes an increase in dental damage. That's what they noticed at the department of dentistry at Radboudumc.

read more

Annual Paper Awards of Research Theme Tumors of the Digestive Tract

4 May 2021

The annual Paper Awards session of the Research Theme Tumors of the Digestive Tract took place at the 22nd of April. The selected candidates prepared wonderful informative movies, that were judged by the public of the RRR and by our patient representatives.

read more